In 20% and 31% of the patients, a >50% and >30% decline, respectively, of the serum tumor marker prostate specific antigen (PSA) was reached with a significant improved progression-free survival in patients with EGFR overexpression [28]. Here, KLK3 is linked to neoplasm.